Compare VENUS REMEDIES with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES LUPIN VENUS REMEDIES/
LUPIN
 
P/E (TTM) x -1.3 46.7 - View Chart
P/BV x 0.1 2.4 3.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   LUPIN
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
LUPIN
Mar-19
VENUS REMEDIES/
LUPIN
5-Yr Chart
Click to enlarge
High Rs126986 12.8%   
Low Rs61720 8.5%   
Sales per share (Unadj.) Rs301.8369.5 81.7%  
Earnings per share (Unadj.) Rs-24.913.4 -185.5%  
Cash flow per share (Unadj.) Rs2.537.4 6.8%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.3303.7 96.6%  
Shares outstanding (eoy) m12.34452.49 2.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.3 13.4%   
Avg P/E ratio x-3.863.6 -5.9%  
P/CF ratio (eoy) x36.722.8 161.0%  
Price / Book Value ratio x0.32.8 11.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,154386,064 0.3%   
No. of employees `0000.917.7 5.2%   
Total wages/salary Rs m39331,513 1.2%   
Avg. sales/employee Rs Th4,026.19,453.8 42.6%   
Avg. wages/employee Rs Th425.01,782.0 23.8%   
Avg. net profit/employee Rs Th-331.8343.0 -96.7%   
INCOME DATA
Net Sales Rs m3,724167,182 2.2%  
Other income Rs m233,640 0.6%   
Total revenues Rs m3,747170,822 2.2%   
Gross profit Rs m39528,822 1.4%  
Depreciation Rs m33810,850 3.1%   
Interest Rs m3543,078 11.5%   
Profit before tax Rs m-27518,534 -1.5%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m329,017 0.4%   
Profit after tax Rs m-3076,066 -5.1%  
Gross profit margin %10.617.2 61.5%  
Effective tax rate %-11.548.7 -23.6%   
Net profit margin %-8.23.6 -227.1%  
BALANCE SHEET DATA
Current assets Rs m2,638138,536 1.9%   
Current liabilities Rs m2,30561,299 3.8%   
Net working cap to sales %8.946.2 19.4%  
Current ratio x1.12.3 50.6%  
Inventory Days Days13584 161.7%  
Debtors Days Days46112 41.2%  
Net fixed assets Rs m4,871127,516 3.8%   
Share capital Rs m123905 13.6%   
"Free" reserves Rs m3,496136,517 2.6%   
Net worth Rs m3,619137,422 2.6%   
Long term debt Rs m1,37466,417 2.1%   
Total assets Rs m7,509279,494 2.7%  
Interest coverage x0.27.0 3.2%   
Debt to equity ratio x0.40.5 78.6%  
Sales to assets ratio x0.50.6 82.9%   
Return on assets %0.63.3 19.3%  
Return on equity %-8.54.4 -192.1%  
Return on capital %1.68.9 17.8%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m059,414 0.0%   
Fx outflow Rs m51722,282 2.3%   
Net fx Rs m-51737,132 -1.4%   
CASH FLOW
From Operations Rs m51416,660 3.1%  
From Investments Rs m-123-32,825 0.4%  
From Financial Activity Rs m-3877,441 -5.2%  
Net Cashflow Rs m4-8,724 -0.0%  

Share Holding

Indian Promoters % 32.9 46.6 70.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 31.9 1.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.1 657.4%  
Shareholders   20,121 98,259 20.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 17, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - STERLING BIOTECH COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS